Stock Scorecard
Stock Summary for Durect Corp (DRRX) - $0.87 as of 4/22/2024 3:40:27 PM EST
Total Score
10 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DRRX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DRRX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DRRX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for DRRX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for DRRX
Financial Details for DRRX
Company Overview |
|
---|---|
Ticker | DRRX |
Company Name | Durect Corp |
Country | USA |
Description | DURECT Corporation, a biopharmaceutical company, researches and develops drugs based on its epigenetic regulator and pharmaceutical programs. The company is headquartered in Cupertino, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/6/2024 |
Stock Price History |
|
Last Day Price | 0.87 |
Last Day Price Updated | 4/22/2024 3:40:27 PM EST |
Last Day Volume | 0 |
Average Daily Volume | 146,109 |
52-Week High | 7.46 |
52-Week Low | 0.47 |
Last Price to 52 Week Low | 85.11% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 99.84 |
Sector PE | 60.50 |
5-Year Average PE | -7.69 |
Free Cash Flow Ratio | 0.91 |
Industry Free Cash Flow Ratio | 12.59 |
Sector Free Cash Flow Ratio | 29.99 |
Current Ratio Most Recent Quarter | 1.28 |
Total Cash Per Share | 0.96 |
Book Value Per Share Most Recent Quarter | 0.49 |
Price to Book Ratio | 1.62 |
Industry Price to Book Ratio | 5.66 |
Sector Price to Book Ratio | 22.08 |
Price to Sales Ratio Twelve Trailing Months | 2.78 |
Industry Price to Sales Ratio Twelve Trailing Months | 5.48 |
Sector Price to Sales Ratio Twelve Trailing Months | 5.16 |
Share Statistics |
|
Total Shares Outstanding | 31,036,000 |
Market Capitalization | 27,001,320 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 1.17% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 21.82% |
Reported EPS 12 Trailing Months | -1.20 |
Reported EPS Past Year | 0.00 |
Reported EPS Prior Year | -1.13 |
Net Income Twelve Trailing Months | -27,624,000 |
Net Income Past Year | -27,624,000 |
Net Income Prior Year | -35,333,000 |
Quarterly Revenue Growth YOY | -19.50% |
5-Year Revenue Growth | -12.94% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 29,680,000 |
Total Cash Past Year | 29,680,000 |
Total Cash Prior Year | 43,483,000 |
Net Cash Position Most Recent Quarter | 13,017,000 |
Net Cash Position Past Year | 13,017,000 |
Long Term Debt Past Year | 16,663,000 |
Long Term Debt Prior Year | 21,170,000 |
Total Debt Most Recent Quarter | 16,663,000 |
Equity to Debt Ratio Past Year | 0.47 |
Equity to Debt Ratio Most Recent Quarter | 0.47 |
Total Stockholder Equity Past Year | 14,783,000 |
Total Stockholder Equity Prior Year | 24,985,000 |
Total Stockholder Equity Most Recent Quarter | 14,783,000 |
Options |
|
Put/Call Ratio | 0.09 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.07 |
MACD Signal | -0.05 |
20-Day Bollinger Lower Band | 0.42 |
20-Day Bollinger Middle Band | 0.86 |
20-Day Bollinger Upper Band | 1.29 |
Beta | 0.88 |
RSI | 41.53 |
50-Day SMA | 2.41 |
200-Day SMA | 9.48 |
System |
|
Modified | 4/22/2024 10:53:17 PM EST |